Stoke Therapeutics Stock Slips as CEO Steps Down [Yahoo! Finance]
Stoke Therapeutics, Inc. (STOK)
Last stoke therapeutics, inc. earnings: 11/12 08:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Stoke Therapeutics shares fell Tuesday after the company announced the resignation of its CEO. Dr. Edward Kaye is stepping down from the position Wednesday, with the company beginning a search immediately. Stoke also topped estimates for the fourth quarter, reporting higher revenue and a smaller loss than expected. Shares of Stoke Therapeutics ( STOK ) slipped Tuesday as the drugmaker said its CEO Dr. Edward Kaye is stepping down from his role. Stoke said Tuesday that Kaye will officially step down as of Wednesday, with board member Ian Smith taking over as interim CEO as it launches a search for a permanent replacement. Kaye will stay on as an advisor through the transition process, the company said. The company has drugs in development to treat conditions such as an infant epilepsy disease called Dravet Syndrome. Separately on Tuesday, Stoke also reported its results for the fourth quarter of 2024. The company reported $22.61 million in revenue, well above the $4.22 mil
Show less
Read more
Impact Snapshot
Event Time:
STOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STOK alerts
High impacting Stoke Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
STOK
News
- Stoke Therapeutics (NASDAQ:STOK) was given a new $50.00 price target on by analysts at UBS Group AG.MarketBeat
- Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at HC Wainwright from $35.00 to $50.00. They now have a "buy" rating on the stock.MarketBeat
- Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? [Yahoo! Finance]Yahoo! Finance
- Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)? [Yahoo! Finance]Yahoo! Finance
- Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting [Yahoo! Finance]Yahoo! Finance
STOK
Earnings
- 11/4/25 - Miss
STOK
Sec Filings
- 12/10/25 - Form 4
- 12/10/25 - Form 4
- 12/8/25 - Form 144
- STOK's page on the SEC website